Abstract

Drug-resistant infectious diseases have increased in recent years. Accordingly, plenty of researches are exploring novel approaches to overcome this problem. In this era, antimicrobial peptides have been identified as potential antibacterial agents. The Modified CM11 (mCM11) was designed with the C-terminal amidation and substitution of lysine with arginine. The designed peptide was synthesized by the solid-phase method and Rink amide p-methyl-benzhydryl amine resin. The synthesized peptide was evaluated using Mass Spectrometry (MS), High-Performance Liquid Chromatography (HPLC), and Circular Dichroism (CD). Finally, the antibacterial, cytotoxic, and apoptotic effect of the mCM11 peptide was investigated. The new peptide indicated a beta-sheet structure with a molecular weight of 1527.50 D and purity of 96. The peptide exerted a potent antimicrobial activity against gram-negative and positive bacteria. The minimum inhibitory concentration (MIC) and minimum bacterial concentration (MBC) ranged from 16 to 64 mu g/ml, and 16 to 128 mu g/ml, respectively. The IC50 of mCM11 was 16 mu g/ml and its cytotoxicity in SH-SY5Y cell line revealed a dose-dependent manner. Also, apoptosis analysis of eukaryotic cells revealed a decline in late apoptosis and necrosis in comparison with untreated cells. The mCM11 indicated a considerable antibacterial effect against a wide range of pathogenic bacterial strains. Further, it did not represent any late apoptotic and necrosis impact on the eukaryotic cell line. All of these findings may confirm the potential role of this new peptide as an effective therapeutic agent.